United Therapeutics Corp

UTHR remains in a corrective pullback below declining EMAs into oversold extremes within its broader uptrend. Mean-reversion eligibility grants a medium-term bullish bias, but short-term timing disfavors entry until price demonstrates support acceptance near the 480–490 zone. Execution is deferred pending clear pullback absorption.

• ↑Pipeline catalysts: Rilinopag & nebulized Tyveso could unlock multi-$B revenues pending 2027 approvals
• ↑Q2 EPS grew to $7.27 from $6.41 YoY despite flat $783M revenues
• ↓Q2 revenue was flat at $783M YoY, showing limited top-line growth